Hydrophobic Interaction Chromatography for Factor VII Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current industrial-scale purification methods for Factor VII polypeptides often result in products with significant amounts of product-related impurities and non-uniform glycosylation patterns, which can affect their clinical efficacy.
Innovation Solution
The use of hydrophobic interaction chromatography (HIC) with specific salt and zwitterion concentrations to reduce late eluting peaks and achieve a uniform glycosylation pattern in Factor VII polypeptide preparations, involving steps such as binding, washing, and elution to collect a purified drug substance with reduced impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used for Factor VII polypeptides, then the purification process is simple and quick, but the product contains significant amounts of product-related impurities and has non-uniform glycosylation patterns
Solution Approach 1:
The purification process is divided into multiple distinct steps: hydrophobic interaction chromatography (HIC) for initial separation, followed by ion exchange chromatography for further purification. This segmentation allows each step to target specific impurities, achieving high purification quality while maintaining process manageability through modular design
Solution Approach 2:
The method utilizes changes in physical and chemical parameters to achieve separation. HIC operates based on hydrophobicity differences under controlled salt concentration conditions, followed by ion exchange chromatography utilizing charge differences. These parameter changes enable selective binding and elution of Factor VII polypeptide from impurities, resolving the contradiction between purification quality and process complexity
2Productivity
If industrial-scale purification is performed, then large quantities of product can be obtained, but the product contains significant impurities including late eluting peaks and glyco-variants
Solution Approach 1:
The HIC step is performed as a preliminary action before the ion exchange chromatography. This preliminary separation removes the bulk of impurities including late eluting peaks and glyco-variants early in the process, allowing the subsequent ion exchange step to focus on fine purification. This approach maintains high productivity while ensuring product purity
Solution Approach 2:
The HIC chromatography system acts as an intermediary between the industrial-scale production and the final purification step. It serves as a buffer that handles the large quantities of product while pre-concentrating the purification task, enabling both high productivity and high purity to be achieved without compromising either objective
3Ease of operation
If the purification process is simplified, then the process is easier to operate and less complex, but the glycosylation pattern remains non-uniform
Solution Approach 1:
The ion exchange chromatography step utilizes controlled changes in ionic strength and pH parameters to selectively bind and elute glycosylated forms of Factor VII. By adjusting these parameters, the process achieves uniform glycosylation patterns while maintaining ease of operation through standard chromatographic techniques that can be easily controlled and replicated
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively reduces product-related impurities by at least 50% and achieves a uniform glycosylation pattern, enhancing the clinical efficacy and stability of Factor VII polypeptide preparations.
Implementation Method 1
contacting the drug substance with a hydrophobic interaction chromatography material under conditions which facilitate binding of a portion of said drug substance to said hydrophobic interaction chromatography material
Implementation Method 2
The inventors have discovered that by following a particular hydrophobic interaction chromatography procedure wherein a salt and/or a zwitterion is used, it is possible to reduce, or virtually eliminate, the presence of late elution peaks in the drug substance
Data Source
AI summary
The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern.